GOLD 2025 Report: Dupilumab, a New Treatment in COPD

Author(s):

M. Bradley Drummond, MD, MHS,MeiLan K. Han, MD, MS

Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.

EP: 1.Overview and Diagnosis of COPD

EP: 2.Risk Factors for COPD

EP: 3.Mortality and Comorbidities with COPD

EP: 4.Health and Economic Burden of COPD

EP: 5.Treatment of COPD Based on Symptoms

EP: 6.GOLD 2025 Report: Prebronchodilator Spirometry and Diagnosis of COPD

EP: 7.GOLD 2025 Report: Lung Microbiome and Chest CT Imaging in COPD

EP: 8.GOLD 2025 Report: Addressing Heart Disease in COPD

EP: 9.Blood Eosinophil Counts in COPD

EP: 10.GOLD 2025 Report: Ensifentrine, a New Treatment in COPD

Now Viewing

EP: 11.GOLD 2025 Report: Dupilumab, a New Treatment in COPD

Video content above is prompted by the following:

The 2025 GOLD recommendations include the addition of dupilumab as the first biologic treatment to reduce the frequency of COPD exacerbations in stable COPD.
Discuss clinical outcomes with dupilumab in the BOREAS and NOTUS phase 3 trials.